These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Pickar JH; Mirkin S Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688 [TBL] [Abstract][Full Text] [Related]
3. Use of SERMs for treatment in postmenopausal women. Pinkerton JV; Thomas S J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794 [TBL] [Abstract][Full Text] [Related]
4. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Pinkerton JV; Goldstein SR Menopause; 2010; 17(3):642-53. PubMed ID: 20107426 [TBL] [Abstract][Full Text] [Related]
6. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL; Chao HT; Cheng MH; Wang PH Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794 [TBL] [Abstract][Full Text] [Related]
7. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Gennari L Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205 [TBL] [Abstract][Full Text] [Related]
9. The future of the new selective estrogen receptor modulators. Palacios S Menopause Int; 2007 Mar; 13(1):27-34. PubMed ID: 17448265 [TBL] [Abstract][Full Text] [Related]
10. Raloxifene for the treatment and prevention of breast cancer? Pappas SG; Jordan VC Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100 [TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males. Kastelan D; Giljevic Z; Kraljevic I; Korsic M Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322 [TBL] [Abstract][Full Text] [Related]
12. Selective modulation of postmenopausal women: cutting the Gordian knot of hormone replacement therapy with breast carcinoma. Diamanti-Kandarakis E; Sykiotis GP; Papavassiliou AG Cancer; 2003 Jan; 97(1):12-20. PubMed ID: 12491500 [TBL] [Abstract][Full Text] [Related]
13. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Maeda T; Ke HZ; Simmons H; Thompson D Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137 [TBL] [Abstract][Full Text] [Related]
14. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Maximov PY; Lee TM; Jordan VC Curr Clin Pharmacol; 2013 May; 8(2):135-55. PubMed ID: 23062036 [TBL] [Abstract][Full Text] [Related]
16. [Which is the better choice, estrogen or SERMs in postmenopausal women?]. Shintani M Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140 [TBL] [Abstract][Full Text] [Related]
17. [Selective estrogen receptor modulators (SERMs) in the practice]. Nagykálnai T Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896 [TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators: the future in menopausal treatment. Palacios S Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612 [TBL] [Abstract][Full Text] [Related]
19. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Johnston SR Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228 [TBL] [Abstract][Full Text] [Related]
20. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient]. Kastelan D; Korsić M Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]